In a report released on February 13, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $90.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Joseph Schwartz’s rating is based on the promising growth trajectory of Ultragenyx Pharmaceutical, particularly highlighted by their solid financial performance in 2024 and optimistic revenue guidance for 2025. The company reported strong product revenues that were in line with expectations, signaling robust demand and efficient operations. Looking forward, the anticipated revenue growth of approximately 17% at the midpoint for 2025 reinforces confidence in the company’s financial health.
Additionally, Schwartz points to the progress in Ultragenyx’s clinical pipeline as a significant factor. The upcoming interim analysis of the ORBIT study for setrusumab in mid-2025 is a key event, with expectations of positive outcomes that could enhance the company’s position in treating osteogenesis imperfecta. The firm’s substantial cash reserves and the potential for other pipeline developments further support the Buy rating, making Ultragenyx a compelling investment opportunity for the upcoming year.
In another report released on February 14, Piper Sandler also maintained a Buy rating on the stock with a $140.00 price target.
RARE’s price has also changed moderately for the past six months – from $51.800 to $43.520, which is a -15.98% drop .